Seeing further.

THAT’S OUR TARGET

We’re advancing our RNA-based treatments so patients with cancers and rare diseases can enjoy the moments that matter.

Learn More

Transforming Immunity. Restoring Hope.

We’re committed to redefining the treatment of certain cancers and rare diseases.

Learn More

Scientists. Believers. People.

At Idera, we’re working hard to translate our nucleic acid science into life-changing medicines.

Discover Idera

The Latest

Keep up with what’s happening at Idera Pharmaceuticals.

News

Idera Announces FDA Orphan Drug Designation for IMO-2125 for the Treatment of Melanoma

CAMBRIDGE, Mass. and EXTON, Pa., June 22, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc.… Read more 

Idera to Present at the Jefferies 2017 Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa., June 05, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc.… Read more 

Idera Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update

IMO-2125 Advances to Phase 2 Clinical Trial in PD-1 Refractory Melanoma CAMBRIDGE, Mass. and… Read more 

Learn More

Events

Tue, 27 Jun 2017 15:09:15 GMT

Idera Pharmaceuticals, Inc. Calendar Events

A Collection of Idera Pharmaceuticals, Inc. Calendar Events… Read more 

Learn More